GLP-1 Evidence

Article

Do GLP-1 drugs protect the kidneys? What the trials measured

Updated 4 min read 37 citations

Analytical chemistry bench fitted with glassware for titration and pH measurement
Jean-Pierre from Cosne-Cours-sur-Loire (Nièvre, Burgundy… · CC BY-SA 2.0 · Wikimedia Commons

Search "ozempic kidney disease" or "semaglutide chronic kidney disease" and you will find a lot of confident claims and very few links to an actual trial. The short version: the kidney signal is one of the better-supported non-weight findings for this drug class, but "protects the kidneys" means something narrower and more specific than most coverage implies — a slowed rate of decline in kidney function and fewer kidney-failure events in trials, not a treatment for kidney disease in general.

What "kidney outcomes" means in these trials

Trials in this area do not ask whether a drug "helps the kidneys." They track a defined composite: a sustained drop in estimated glomerular filtration rate (eGFR), progression to kidney failure, need for dialysis or transplant, or death from kidney or cardiovascular causes. A 2025 systematic review and meta-analysis of randomised trials in patients who already had chronic kidney disease examined GLP-1 receptor agonists against this kind of composite and reported consistent benefit [11]. A second, independent 2025 meta-analysis of randomised controlled trials reached the same conclusion looking at kidney and cardiovascular outcomes together [9].

This is not a brand-new finding dressed up for 2025. Earlier pooled analyses of cardiovascular outcome trials had already flagged a kidney signal riding alongside the cardiovascular one, going back to a 2019 systematic review and meta-analysis of cardiovascular outcome trials in type 2 diabetes [19] and confirmed again in a 2021 update using the same approach [37]. The kidney finding has been reproduced across several independent pooling exercises rather than resting on one headline trial — which is a meaningfully different evidence base than a single positive study.

Tirzepatide's own kidney data

The dual GIP/GLP-1 agonist has its own dedicated evidence. A post-hoc analysis of the SURPASS-4 trial compared tirzepatide against insulin glargine on kidney outcomes in people with type 2 diabetes and found benefit for tirzepatide on the composite renal endpoint [26]. That is a comparison against an active treatment known to be glucose-lowering, not a placebo, which strengthens the case that the effect is not simply "any glucose control helps the kidneys a bit."

Why weight-mediated versus direct matters here

The obesity-kidney relationship is itself well established in the literature: excess weight is an independent driver of kidney disease progression through several mechanisms, including glomerular hyperfiltration [35]. That creates the same interpretive problem this site raises on the cardiovascular outcomes page: a drug that produces large, sustained weight loss would be expected to help the kidneys somewhat regardless of any direct GLP-1 receptor effect on renal tissue. The trials as designed cannot cleanly separate "the kidneys got better because the person weighs less and has better blood pressure and glucose control" from "GLP-1 receptor activation has a direct protective mechanism in the kidney." Both are plausible; the trial data is agnostic between them, and it does not need to resolve that question for the finding to be clinically useful.

Reading the evidence at a glance

QuestionWhat the data showsConfidence
Does the drug class slow kidney function decline in people who already have CKD?Yes, across at least two independent 2025 meta-analyses of RCTsReasonably strong
Is the effect specific to one drug, or class-wide?Evidence spans multiple GLP-1 and dual-agonist molecules, including a head-to-head-style comparison for tirzepatideModerate — most depth is in diabetes populations
Is it a direct kidney effect or a downstream effect of weight and glucose control?Unresolved; both mechanisms are biologically plausibleOpen question
Does this mean the drug treats kidney disease on its own?No — it is adjunct evidence within diabetes and obesity care, not a kidney-disease indication in the sense a nephrology-specific drug would beDo not overstate

What this does not tell you

None of these trials enrolled people specifically because they had kidney disease and no diabetes or obesity — the populations are diabetes cohorts and, in the newer reviews, mixed CKD cohorts already on other kidney-protective therapy. That matters for anyone reading the headline "GLP-1 drugs cut kidney failure risk" and wondering if it applies to them specifically. It also does not tell you anything about dosing adjustments needed in advanced kidney impairment, which is a pharmacokinetic question the cited trials were not built to answer.

Common questions

Does this mean semaglutide or tirzepatide can replace an ACE inhibitor or SGLT2 inhibitor for kidney protection?
No trial has tested that substitution. The kidney benefit shows up in populations who were, in the main, already receiving standard-of-care kidney and cardiovascular medication. This is evidence for an additive benefit, not a replacement.
Is the kidney benefit bigger in people with more advanced kidney disease?
The 2025 CKD-specific review found benefit within a population that already had chronic kidney disease, which is a more direct answer than the earlier diabetes-cohort analyses could give, but subgroup effects by CKD stage are not something a short summary can respond to reliably — that detail sits inside the full review.
Does weight loss alone, without a GLP-1 drug, do the same thing for the kidneys?
Plausibly a comparable amount for the weight-mediated portion of the effect, but there is no head-to-head trial comparing equivalent weight loss achieved by diet against these drugs on kidney-specific endpoints.
Should someone with kidney disease ask about these drugs?
That is a conversation for a nephrologist or the physician managing kidney and diabetes care together, not a decision to make from a summary article. This article is for informational purposes and is not medical advice; talk to a clinician about your own situation.
Labelled chemical bottles standing together on a laboratory bench
564dude · CC BY-SA 3.0 · Wikimedia Commons
The evidence behind this page A stacked bar showing the composition of the 37 publications cited on this page by study type. 201322meta-analysis (20)randomised trial (13)review (2)other (2)
37 publications, 2018–2026. That is a mix with both trials and syntheses in it, which is the position from which a claim about cause is reasonable. Source: this page’s own citation list, below.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis Peng TR, Lin HH, Tseng TL, et al. · British journal of clinical pharmacology · 2026 · Meta-analysis DOIPubMed 42273973Full text
  2. Beyond Monotherapy: The Superior Efficacy of Combined GLP-1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta-Analysis AbdelMagid AM, Kamel AM, Farid SF · Pharmacotherapy · 2026 · Meta-analysis DOIPubMed 41947610
  3. Efficacy of tirzepatide, lanifibranor, and resmetirom in metabolic dysfunction-associated steatotic liver disease: a meta-analysis of high-quality randomized controlled trials Zhao S, Tian F, Yu L, et al. · Internal and emergency medicine · 2026 · Meta-analysis DOIPubMed 41917519
  4. Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis Alper A, Fagin A, Karthikeyan A, et al. · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026 · Meta-analysis DOIPubMed 42458197
  5. The Impact of GLP-1-Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta-Analysis Chuang SM, Liu SC, Chien KL, et al. · Diabetes, obesity & metabolism · 2026 · Meta-analysis DOIPubMed 42219271Full text
  6. Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis Shokravi A, Seth J, Mancini GBJ · Cardiovascular diabetology · 2026 · Meta-analysis DOIPubMed 41761267Full text
  7. Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis Elganyny MKE, Elganyni AKE, Maskji HA, et al. · La Clinica terapeutica · 2026 · Meta-analysis DOIPubMed 42340790
  8. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes Natale P, Green SC, Tunnicliffe DJ, et al. · The Cochrane database of systematic reviews · 2025 · Meta-analysis DOIPubMed 39963952Full text
  9. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  10. Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis Cleto AS, Schirlo JM, Beltrame M, et al. · International journal of obesity (2005) · 2025 · Meta-analysis DOIPubMed 39396098
  11. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials Chen JY, Hsu TW, Liu JH, et al. · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025 · Meta-analysis DOIPubMed 39863261
  12. Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis Shokravi A, Seth J, Mancini GBJ · Cardiovascular diabetology · 2025 · Meta-analysis DOIPubMed 41029853Full text
  13. Evaluation of three mechanisms of action (SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas) in treating type 2 diabetes with heart failure: a systematic review and network meta-analysis of RCTs Gao H, Wei Q, Zou A, et al. · Frontiers in endocrinology · 2025 · Meta-analysis DOIPubMed 40556828Full text
  14. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials Apperloo EM, Neuen BL, Fletcher RA, et al. · The lancet. Diabetes & endocrinology · 2024 · Meta-analysis DOIPubMed 38991584
  15. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Shi Q, Nong K, Vandvik PO, et al. · BMJ (Clinical research ed.) · 2023 · Meta-analysis DOIPubMed 37024129Full text
  16. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis Sattar N, McGuire DK, Pavo I, et al. · Nature medicine · 2022 · Meta-analysis DOIPubMed 35210595Full text
  17. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease Zhang Y, Jiang L, Wang J, et al. · Cardiovascular diabetology · 2022 · Meta-analysis DOIPubMed 36335326Full text
  18. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  19. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  20. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis Bethel MA, Patel RA, Merrill P, et al. · The lancet. Diabetes & endocrinology · 2018 · Meta-analysis DOIPubMed 29221659
  21. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study Harrison SA, Frias JP, Lucas KJ, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · Randomised controlled trial DOIPubMed 38447814
  22. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight Malhotra A, Grunstein RR, Azarbarzin A, et al. · Sleep medicine · 2025 · Randomised controlled trial DOIPubMed 41135142Full text
  23. Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial) Agarwal R, Green JB, Heerspink HJL, et al. · Diabetes care · 2025 · Randomised controlled trial DOIPubMed 40968755Full text
  24. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial Deanfield J, Verma S, Scirica BM, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39181597
  25. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Gastaldelli A, Cusi K, Fernández Landó L, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468325
  26. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial Heerspink HJL, Sattar N, Pavo I, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 36152639
  27. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial Klausen MK, Jensen ME, Møller M, et al. · JCI insight · 2022 · Randomised controlled trial DOIPubMed 36066977Full text
  28. [Focus on tirzepatide, a dual unimolecular GIP-GLP-1 receptor agonist in type 2 diabetes] Scheen AJ, Radermecker RP, Paquot N · Revue medicale suisse · 2022 · Randomised controlled trial DOIPubMed 36004653
  29. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes Gerstein HC, Sattar N, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34215025
  30. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure Marso SP, Baeres FMM, Bain SC, et al. · Journal of the American College of Cardiology · 2020 · Randomised controlled trial DOIPubMed 32164886
  31. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes Hartman ML, Sanyal AJ, Loomba R, et al. · Diabetes care · 2020 · Randomised controlled trial DOIPubMed 32291277Full text
  32. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet (London, England) · 2019 · Randomised controlled trial DOIPubMed 31189511
  33. Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Van Kleef LA, Michel M, Alkhouri N, et al. · Drug design, development and therapy · 2026 · Review DOIPubMed 41868171Full text
  34. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics Nicholls SJ, Bhatt DL, Buse JB, et al. · American heart journal · 2024 · Clinical trial DOIPubMed 37758044
  35. Chronic Kidney Disease and Obesity Hojs R, Ekart R, Bevc S, et al. · Nephron · 2023 · Review DOIPubMed 37271131
  36. New Drug: Tirzepatide (Mounjaro(™)) Gettman L · The Senior care pharmacist · 2023 · Journal article DOIPubMed 36751934
  37. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Sattar N, Lee MMY, Kristensen SL, et al. · The lancet. Diabetes & endocrinology · 2021 · Journal article DOIPubMed 34425083